Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and ...

Manufacturing and Supply Chain Readiness : The Company has secured agreements with leading U.S. manufacturers, including Thermo Fisher Scientific and Cambrex, to support a secure supply chain for the ...
The Manila Times

Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and ...

The Collaboration Framework marks Adial’s first step towards commercial partnership and establishing an exclusive European pathway as AD04 advances toward pivotal Phase 3 development ...

Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in ...

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of treatments ...